carboxyamido-triazole has been researched along with Benign Neoplasms in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (46.67) | 18.2507 |
| 2000's | 7 (46.67) | 29.6817 |
| 2010's | 1 (6.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Azad, N; Figg, WD; Gardner, E; Graves, C; Imamura, CK; Kohn, EC; Kotz, H; Minasian, L; Perroy, A; Raggio, M; Sarosy, GA | 1 |
| Guo, L; Ju, R; Li, J; Wu, D; Ye, C; Zhang, D | 1 |
| Doong, H; Kassis, J; Kohn, EC; Patton, AM | 1 |
| DeMario, M; Desai, AA; Fleming, GF; Innocenti, F; Janisch, L; Ramirez, J; Ratain, MJ; Shepard, D | 1 |
| Friedlander, ML; Kohn, EC; Qu, XJ; Yang, JL; Yu, Y | 1 |
| Christian, M; Cole, K; Davis, PA; Figg, WD; Goldspiel, B; Jacob, J; Kohn, EC; Link, CJ; Liotta, LA; Reed, E; Sarosy, G | 1 |
| Alessandro, R; Kohn, EC; Spoonster, J; Wersto, RP | 1 |
| Kuwano, M; Ono, M | 1 |
| Alberti, D; Arzoomanian, RZ; Berlin, J; Cleary, J; Feierabend, C; Hutson, P; Rago, RP; Tutsch, KD; Wilding, G | 1 |
| Bauer, KS; Davis, PA; Figg, WD; Kohn, EC; Liotta, LA; Reed, E; Sarosy, GA; Soltis, MJ; Thompkins, A | 1 |
| Boudoulas, S; Cole, KA; Davis, PA; Figg, WD; Goldspiel, B; Jacob, J; Piscitelli, SC; Reed, E; Soltis, MJ; Steinberg, SM | 1 |
| Bauer, KS; Davis, P; Figg, WD; Kohler, D; Kohn, EC; Lush, RM; Reed, E; Steinberg, SM | 1 |
| Bauer, KS; Bostick-Bruton, F; Figg, WD; Fuse, E; Goldspiel, B; Kohn, EC; Kulpa, V; Liotta, LA; Minasian, L; Noone, M; Pluda, J; Reed, E; Sarosy, GA; Tompkins, A | 1 |
| Libutti, SK; Zogakis, TG | 1 |
| Alberti, D; Arzoomanian, RZ; Berlin, J; Binger, K; Dresen, A; Feierabend, C; Marnocha, R; Pluda, J; Tutsch, KD; Wilding, G | 1 |
4 review(s) available for carboxyamido-triazole and Benign Neoplasms
| Article | Year |
|---|---|
Calcium as a molecular target in angiogenesis.
Topics: Calcium; Calcium Channel Blockers; Calcium Signaling; Cell Membrane; Humans; Neoplasms; Neovascularization, Pathologic; Neovascularization, Physiologic; Triazoles | 2003 |
Signal transduction as a therapeutic target.
Topics: Animals; Antineoplastic Agents; Calcium; Calcium Channel Blockers; Clinical Trials as Topic; Growth Substances; GTP-Binding Proteins; Humans; Ion Channel Gating; Ion Channels; Mice; Neoplasm Proteins; Neoplasms; Oncogenes; Phosphatidylinositol 3-Kinases; Phosphatidylinositol Diacylglycerol-Lyase; Phosphoric Diester Hydrolases; Phosphotransferases (Alcohol Group Acceptor); Protein Kinase C; Protein-Tyrosine Kinases; Proto-Oncogene Proteins p21(ras); Receptor Protein-Tyrosine Kinases; Signal Transduction; Triazoles | 1996 |
[Development of anti tumor agents targeting angiogenesis].
Topics: Antineoplastic Agents; Clinical Trials as Topic; Cyclohexanes; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Hydroxamic Acids; Interferon-alpha; Interleukin-12; Neoplasms; Neovascularization, Pathologic; O-(Chloroacetylcarbamoyl)fumagillol; Phenylalanine; Platelet Factor 4; Polysaccharides, Bacterial; Sesquiterpenes; Thalidomide; Thiophenes; Triazines; Triazoles; Tumor Cells, Cultured | 1997 |
General aspects of anti-angiogenesis and cancer therapy.
Topics: Angiogenesis Inhibitors; Animals; Antibodies; Clinical Trials as Topic; Collagen; Cyclohexanes; Endostatins; Endothelial Growth Factors; Fatty Acids, Unsaturated; Humans; Interleukin-12; Lymphokines; Matrix Metalloproteinase Inhibitors; Matrix Metalloproteinases; Neoplasms; O-(Chloroacetylcarbamoyl)fumagillol; Peptide Fragments; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Receptors, Vascular Endothelial Growth Factor; Receptors, Vitronectin; RNA, Catalytic; Sesquiterpenes; Suramin; Thalidomide; Triazoles; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2001 |
9 trial(s) available for carboxyamido-triazole and Benign Neoplasms
| Article | Year |
|---|---|
A phase I study of paclitaxel and continuous daily CAI in patients with refractory solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Treatment Outcome; Triazoles; Young Adult | 2009 |
A phase I trial of pharmacokinetic modulation of carboxyamidotriazole (CAI) with ketoconazole in patients with advanced cancer.
Topics: Adult; Aged; Antifungal Agents; Antineoplastic Agents; Capsules; Chemistry, Pharmaceutical; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Female; Humans; Ketoconazole; Male; Middle Aged; Neoplasms; Triazoles | 2004 |
Clinical investigation of a cytostatic calcium influx inhibitor in patients with refractory cancers.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Calcium Channel Blockers; Female; Humans; Male; Middle Aged; Neoplasms; Triazoles | 1996 |
Phase I clinical and pharmacokinetic study of oral carboxyamidotriazole, a signal transduction inhibitor.
Topics: Antineoplastic Agents; Capsules; Digestive System; Drug Administration Schedule; Female; Gels; Hematopoiesis; Humans; Male; Middle Aged; Neoplasms; Nervous System; Signal Transduction; Triazoles | 1997 |
Phase I trial of micronized formulation carboxyamidotriazole in patients with refractory solid tumors: pharmacokinetics, clinical outcome, and comparison of formulations.
Topics: Adult; Aged; Antineoplastic Agents; Drug Administration Schedule; Drug Compounding; Female; Humans; Male; Middle Aged; Neoplasms; Triazoles | 1997 |
Pharmacokinetics of orally administered carboxyamido-triazole, an inhibitor of calcium-mediated signal transduction.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Calcium; Chemistry, Pharmaceutical; Dose-Response Relationship, Drug; Female; Humans; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Neoplasms; Signal Transduction; Triazoles | 1995 |
Pharmacokinetics and relative bioavailability of carboxyamido-triazole with respect to food and time of administration: use of a single model for simultaneous determination of changing parameters.
Topics: Adult; Antineoplastic Agents; Area Under Curve; Biological Availability; Cohort Studies; Cross-Over Studies; Female; Food-Drug Interactions; Humans; Male; Middle Aged; Neoplasms; Triazoles | 1998 |
A phase I trial of carboxyamido-triazole and paclitaxel for relapsed solid tumors: potential efficacy of the combination and demonstration of pharmacokinetic interaction.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; Inhibitory Concentration 50; Male; Mice; Mice, Nude; Middle Aged; Neoplasms; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Recurrence; Time Factors; Treatment Outcome; Triazoles; Tumor Cells, Cultured | 2001 |
Phase I and pharmacokinetic study of a micronized formulation of carboxyamidotriazole, a calcium signal transduction inhibitor: toxicity, bioavailability and the effect of food.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biological Availability; Calcium; Calcium Channel Blockers; Capsules; Diet Therapy; Drug Administration Schedule; Female; Gels; Hematopoiesis; Humans; Intestinal Absorption; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Nervous System; Triazoles | 2002 |
2 other study(ies) available for carboxyamido-triazole and Benign Neoplasms
| Article | Year |
|---|---|
Inhibition of pro-inflammatory cytokines in tumour associated macrophages is a potential anti-cancer mechanism of carboxyamidotriazole.
Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols; Arthritis, Experimental; Carcinoma, Lewis Lung; Coculture Techniques; Cytokines; Dexamethasone; Macrophages; Macrophages, Peritoneal; Male; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Neoplasms; Rats, Wistar; Triazoles; Tumor Microenvironment; Tumor Necrosis Factor-alpha | 2012 |
Selective sensitivity to carboxyamidotriazole by human tumor cell lines with DNA mismatch repair deficiency.
Topics: Antineoplastic Agents; Apoptosis; Calcium Channel Blockers; Cell Cycle; Cell Line, Tumor; Chromosomes, Human; Colonic Neoplasms; Colorimetry; DNA Mismatch Repair; Drug Screening Assays, Antitumor; Female; Fluorouracil; Humans; Male; Neoplasm Invasiveness; Neoplasms; Nifedipine; Ovarian Neoplasms; Prostatic Neoplasms; Transfection; Triazoles; Urinary Bladder Neoplasms | 2008 |